Ruxolitinib Switch-Maintenance Prophylaxis of GVHD
Randomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation After Intermediate-Dose Post-Transplant Cyclophosphamide (Rux Switch-Maintenance in Intermediate PTCY: RuSMa-PTCY) in Comparison to Full-Dose PTCY
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 40 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Collaborators
- Incyte Corporation
- Tags
- JAK1 Inhibitor, Tyrosine Kinase (TK) Inhibitor, JAK2 Inhibitor, Randomization, Maintenance
- Trial Type
- Supportive
- Last Update
- SparkCures ID
- 2223
- NCT Identifier
- NCT07359859
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.